Cargando…

Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia

BACKGROUND: Hydromethylthionine is a potent inhibitor of pathological aggregation of tau and TDP-43 proteins. OBJECTIVE: To compare hydromethylthionine treatment effects at two doses and to determine how drug exposure is related to treatment response in bvFTD. METHODS: We undertook a 52-week Phase I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiells, Helen, Schelter, Bjoern O., Bentham, Peter, Baddeley, Thomas C., Rubino, Christopher M., Ganesan, Harish, Hammel, Jeffrey, Vuksanovic, Vesna, Staff, Roger T., Murray, Alison D., Bracoud, Luc, Wischik, Damon J., Riedel, Gernot, Gauthier, Serge, Jia, Jianping, Moebius, Hans J., Hardlund, Jiri, Kipps, Christopher M., Kook, Karin, Storey, John M.D., Harrington, Charles R., Wischik, Claude M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306898/ https://www.ncbi.nlm.nih.gov/pubmed/32280089 http://dx.doi.org/10.3233/JAD-191173

Ejemplares similares

Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease
por: Schelter, Bjoern O., et al.
Publicado: (2019)

Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier
por: Bentham, Peter, et al.
Publicado: (2021)

Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia
por: Vuksanović, Vesna, et al.
Publicado: (2021)

Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice
por: Kondak, Constantin, et al.
Publicado: (2023)

Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks
por: Schwab, Karima, et al.
Publicado: (2021)

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
por: Wilcock, Gordon K., et al.
Publicado: (2017)

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
por: Wischik, Claude M., et al.
Publicado: (2022)

Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants
por: Arastoo, Mohammad, et al.
Publicado: (2023)

Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development
por: Wischik, Claude M., et al.
Publicado: (2018)

Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer’s disease and frontotemporal lobar degeneration
por: Cranston, Anna L, et al.
Publicado: (2020)

Vascular risk factors affect different brain regions in people with Alzheimer’s disease
por: Tripathi, S., et al.
Publicado: (2022)

Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia
por: Lemke, Nora, et al.
Publicado: (2021)

HMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine
por: Santos, Renato X., et al.
Publicado: (2022)

Big queues
por: Ganesh, Ayalvadi, et al.
Publicado: (2004)

A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy
por: Schwab, Karima, et al.
Publicado: (2018)

Variably protease‐sensitive prionopathy mimicking frontotemporal dementia
por: Aizpurua, Miren, et al.
Publicado: (2019)

Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration
por: Melis, V., et al.
Publicado: (2014)

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease
por: Lai, Robert Y. K., et al.
Publicado: (2016)

Erratum: Lai, R.Y.K.; Harrington, C.R.; Wischik, C.M. Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease. Biomolecules 2016, 6, 19
por: Lai, Robert Y. K., et al.
Publicado: (2016)

Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic
por: Mattocks, Kristin M., et al.
Publicado: (2022)

Solid-state NMR of paired helical filaments formed by the core tau fragment tau(297-391)
por: Al-Hilaly, Youssra K., et al.
Publicado: (2022)

Structural Identification of Individual Helical Amyloid Filaments by Integration of Cryo-Electron Microscopy-Derived Maps in Comparative Morphometric Atomic Force Microscopy Image Analysis
por: Lutter, Liisa, et al.
Publicado: (2022)

Detection of time-, frequency- and direction-resolved communication within brain networks
por: Crouch, Barry, et al.
Publicado: (2018)

Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model
por: Riedel, Gernot, et al.
Publicado: (2020)

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models
por: Melis, Valeria, et al.
Publicado: (2015)

Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s Disease
por: Arastoo, Mohammad, et al.
Publicado: (2020)

Brain morphometric similarity and flexibility
por: Vuksanović, Vesna
Publicado: (2022)

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease
por: Harrington, Charles R., et al.
Publicado: (2015)

Naming and conceptual understanding in frontotemporal dementia
por: Snowden, Julie S., et al.
Publicado: (2019)

Dynamics of large-scale neuronal networks of the human cortex functional connectivity
por: Vuksanović, Vesna, et al.
Publicado: (2012)

Modeling brain functional connectivity at rest
por: Vuksanović, Vesna, et al.
Publicado: (2013)

Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
por: Oakley, Sebastian S., et al.
Publicado: (2020)

Oxidative Stress Conditions Result in Trapping of PHF-Core Tau (297–391) Intermediates
por: Maina, Mahmoud B., et al.
Publicado: (2021)

Tau (297‐391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer’s disease brain
por: Al‐Hilaly, Youssra K., et al.
Publicado: (2019)

Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis
por: Zabala-Findlay, Alex, et al.
Publicado: (2023)

Auditory conflict and congruence in frontotemporal dementia
por: Clark, Camilla N., et al.
Publicado: (2017)

Genetics of frontotemporal lobar degeneration
por: Aswathy, P. M., et al.
Publicado: (2010)

Phenocopy syndrome of frontotemporal dementia
por: Martins, D., et al.
Publicado: (2021)

The functional neuroanatomy of emotion processing in frontotemporal dementias
por: Marshall, Charles R, et al.
Publicado: (2019)

Heritability in frontotemporal tauopathies
por: Forrest, Shelley L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s0ugqbqk1mcgqql6b75qg7vlgq